eGenesis Raises $191 Million for Human-Compatible Engineered Organs

eGenesis closes $191 million Series D financing to advance human-compatible engineered organs and lead product for kidney transplantation.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here